Literature DB >> 20801003

Rabies and African bat lyssavirus encephalitis and its prevention.

Mary Warrell1.   

Abstract

Unlike any other human infection, encephalitis caused by dog rabies virus is always fatal. Rabies and other lyssaviruses have been found in unexpected places, and human disease, especially paralytic rabies, has gone unrecognised. Evidence is emerging that rabies-related bat lyssaviruses are enzootic across Europe, Africa, Asia and Australia, but none has been detected in the Americas. The epidemiology and origins of African lyssaviruses are discussed. Ideal rabies prophylaxis (pre-exposure immunisation followed by post-exposure booster vaccination) has proved 100% effective; hence all human deaths result from failure of prevention. Rabies vaccines of known quality are unaffordable for the majority in Africa. Although intradermal regimens requiring <40% of the usual vaccine dose are economical and are recommended by the World Health Organization, several problems have inhibited their use. A new, simplified, economical post-exposure vaccine regimen that uses an initial dose of intradermal injections at four sites overcomes many of the difficulties of the previous methods: it is at least as immunogenic as the standard intramuscular course of tissue-culture vaccine; is safer in inexperienced hands; requires fewer than two ampoules of vaccine and only three instead of five clinic visits. Recent data should increase the confidence of physicians to use the World Health Organization-accredited rabies vaccines more efficiently and at lower cost.
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801003     DOI: 10.1016/j.ijantimicag.2010.06.021

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

2.  Quantitative characterization of the B cell receptor repertoires of human immunized with commercial rabies virus vaccine.

Authors:  Pingsen Zhao; Sharula Guo; Zhixiong Zhong; Songtao Yang; Xianzhu Xia
Journal:  Hum Vaccin Immunother       Date:  2021-08-03       Impact factor: 4.526

3.  Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.

Authors:  Leonard Both; Craig van Dolleweerd; Edward Wright; Ashley C Banyard; Bianca Bulmer-Thomas; David Selden; Friedrich Altmann; Anthony R Fooks; Julian K-C Ma
Journal:  FASEB J       Date:  2013-01-31       Impact factor: 5.191

4.  Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.

Authors:  Craig J van Dolleweerd; Audrey Y-H Teh; Ashley C Banyard; Leonard Both; Hester C T Lotter-Stark; Tsepo Tsekoa; Baby Phahladira; Wonderful Shumba; Ereck Chakauya; Claude T Sabeta; Clemens Gruber; Anthony R Fooks; Rachel K Chikwamba; Julian K-C Ma
Journal:  J Infect Dis       Date:  2014-02-07       Impact factor: 5.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.